Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants
Genprex, Inc. (GNPX)
Last genprex, inc. earnings: 11/14 12:08 pm
Check Earnings Report
Company Research
Source: Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, announced today that it closed its previously announced common stock offering priced at-the-market under Nasdaq rules. The Company sold an aggregate of 5,000,000 shares of its common stock at a price of $3.50 per share for gross proceeds to the Company of $17.5 million, before deducting commissions and estimated offering expenses. There were no warrants issued in the offering.A.G.P./Alliance Global Partners acted as the lead placement agent for the offering, and Joseph Gunnar & Co., LLC acted as co-placement agent for the offering.The Company intends to use the net proceeds from the offering to advance its drug development programs and for working capital and general corporate purposes.“The successful closing of this transacti
Show less
Read more
Impact Snapshot
Event Time:
GNPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GNPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNPX alerts
High impacting Genprex, Inc. news events
Weekly update
A roundup of the hottest topics
GNPX
News
- Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung CancerPR Newswire
- Genprex doses first subject in expansion part of lung cancer gene therapy trial [Yahoo! Finance]Yahoo! Finance
- Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerPR Newswire
- Genprex Advances Cancer Trials and Diabetes Therapy [Yahoo! Finance]Yahoo! Finance
GNPX
Sec Filings
- 2/12/25 - Form 8-K
- 1/24/25 - Form S-8
- 1/23/25 - Form 8-K
- GNPX's page on the SEC website